Compare Cytokinetics Inc (CYTK) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Warner Music Group Corp — how do they compare? Cytokinetics Inc trades at $62.77 (market cap $8.62B), while Warner Music Group Corp trades at $28.95 (market cap $15.12B). The key difference: Warner Music Group Corp is the larger of the two by market cap, and Warner Music Group Corp pays a 2.77% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Warner Music Group Corp for 96 Days on average.
| CYTK | WMG | |
|---|---|---|
Market Cap | $8.62B | $15.12B |
Volume | 2,594,626 | 2,966,414 |
Sector | Health | Media |
52-Week High | $87.26 | $34.72 |
52-Week Low | $54.76 | $23.65 |
Typical Hold Time | 19 Days | 96 Days |
Enterprise Value | $8.72B | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
WMG trades at $28.875, up 2.54% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.38, beating expectations, and has a strong analyst consensus of 'Buy' with a $39.50 price target. Recent news highlights AI partnerships and licensing renewals as growth catalysts.
Outlook remains positive due to streaming growth and AI initiatives, but risks include competitive pressures and margin volatility. The stock offers upside potential from current levels if execution continues, though investor caution is warranted near-term given elevated RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
